Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing

Multiple myeloma (MM) is a hematologic neoplasm that develops after transformation and excessive growth of plasma cells in the bone marrow. MM is characterized by heterogeneous genetic abnormalities and an extensive range of clinical outcomes. The marked variability of responses and the limited clinical prognostic value of the current genetic information justify the need to identify new biomarkers of response and develop personalized medicine strategies. The recent introduction of next-generation sequencing technologies has considerably advanced our understanding of the biological features of MM. Accordingly, we used a targeted deep sequencing panel, applying the highest read depth to date, to detect minor subclones and evaluated their impact on response to treatment. We also integrated these data with the clinical features of a very homogeneous cohort of patients to unearth new patterns of genetic alterations and gain new insights into the complexity of the clonal and subclonal architecture of MM.

We analyzed 79 tumor samples from newly diagnosed MM patients enrolled in the GEM10MAS65 clinical trial (registered at www.clinicaltrials.gov as #NCT01237249). This phase II study enrolled patients older than 65 years, and randomly assigned them to one of two treatment arms: sequential melphalan/prednisone/bortezomib (MPV) followed by lenalidomide/low-dose dexamethasone (Rd), or alternating MPV with Rd. This clinical trial was carried out in compliance with the Helsinki Declaration: it was approved by the appropriate research

Figure 1. Mutated genes and parallel clonal evolution. (A) Fifty-four genes were mutated in 79 newly diagnosed MM patients. KRAS, DIS3, NRAS, BRAF and TP53 mutations accounted for 42% of all the mutations. (B) MAX (right and up) and DIS3 (left and down) showed concomitant mutations within the same patient. The proximity between subclonal mutations enabled us to detect that variants were in different sequencing reads, indicating a possible parallel subclonal evolution.
Ethics Committees and all participants provided written informed consent before inclusion. The median time to progression of this cohort of patients was 26.4 months and the median follow up was 31.5 months. Plasma cells were enriched from bone marrow aspirates using anti-CD138⁺ immunomagnetic beads obtaining a purity higher than 85% in all cases and only 20 ng of DNA were used for library construction. The panel screens 77 genes that are frequently mutated in MM, including those related to critical pathophysiological pathways, genes associated with drug resistance, or those targetable by molecular drugs (Online Supplementary Table S1). The average coverage depth for CD138⁺ and CD138⁻ samples was 1600 × and 900 ×, respectively. The minimum coverage of the detected variants was 20 ×, and the average coverage was 370 ×. We applied two different bioinformatics pipelines developed by Thermofisher (Ion reporter 5.0) and by the Spanish National Cancer Research Center (Rubioseq, http://rubioseq.bioinfo.cnio.es/). We also sequenced 11 germline fractions available to confirm that most of the germinal variants had been correctly excluded by our conservative filter criteria.

We identified 168 non-synonymous missense/stop-loss single variants, of which 81 (48%) were predicted to be pathogenic by SIFT and PolyPhen-2, and 61 (36%) have been described in the COSMIC database. Eighty-five percent of patients harbored at least one mutation, with there being a median of 2.1 mutations per patient. Mutations were detected in 53 genes, although the following five genes accounted for 42% of the total

---

**Figure 2. Clonal and subclonal heterogeneity and variant read frequency distributions.** (A) Fifty percent of mutations (85/168) had a variable read frequency (VRF) <25%, and almost half of them (46/168) had a VRF <10%. These values highlight the importance of detecting variants at very low frequencies in newly diagnosed patients. (B) Distribution of the detected variants in the most frequently mutated genes. The number of patients harboring the mutations is indicated below the name of the gene. DIS3 was the only gene in which a mutation VRF >50% was found.
number of mutations: KRAS (21.5% of patients), DIS3 (19%), NRAS (16.5%), BRAF (10.1%) and TP53 (8.8%) (Figure 1A). The RAS pathway was the most recurrently mutated, present in 48% (39/79) of patients. Seventy-two and 100% of KRAS and NRAS mutations, respectively, were detected at the hotspot codons 12, 13 and 61, and the targetable BRAF V600E activating mutation was detected in one patient. KRAS and BRAF mutations were co-existent in three patients, while RAS was always mutated exclusively. NF-κB was the second most frequently mutated pathway in our cohort, accounting for 15% of all mutations; mutations were found in the genes of 25% of the patients (19/79), including the adapter signaling genes TRAF3 (1 nonsense and 4 missense) and TRAF2 (8 missense). All were predicted to be pathogenic by SIFT and PolyPhen-2. Other pathways that were altered in our cohort were MYC, in 11% of patients (9/79), and Cereblon and Cyclin, each found in 9% of patients (7/79). Multiple mutations in the same gene were observed in 12 patients, affecting DIS3 (n=4), KRAS
The VRF of most of the mutations in the landscape, with 50% of variants (85/170) having a VRF below 25% and 27% (46/170) having a VRF below 10% (Figure 2A). The VRF of most of the mutations in KRAS, BRAF, NRAS and TP53 was lower than 40%, while that of DIS3 mutations showed a broader range (2% to 85%) (Figure 2B). The DIS3 gene had the largest number of low VRF mutations (5/20), all of which were considered to be pathogenic by SIFT and PolyPhen-2, and four of which were located in hotspots of the catalytic RNB domain (Online Supplementary Figure S1D). We also evaluated the impact on survival of each individual mutated gene, and of genes grouped according to their pathways. No significant impact on survival was observed for KRAS, NRAS, BRAF or DIS3 genes or for the RAS and NF-kB pathways. The existence of multiple mutations in the same gene or the number of subclonal mutations (<40% VRF) did not affect patients’ survival. However, TP53 mutations were associated with a negative impact on progression-free survival and overall survival (P=0.019 and P=0.004, respectively) (Figure 3A). Patients with mutations in the Cereblon pathway had significantly shorter progression-free survival and overall survival (P=0.040 and P=0.0001, respectively) (Figure 3B). We also noted a negative impact on progression-free survival and overall survival as a function of the number of mutations: patients with more than three mutations (>1 mutation per 61 kb of DNA analyzed) relapsed and died prematurely (P=0.033 and P=0.002, respectively) (Figure 3C). We performed multivariate survival analysis using a Cox regression model with the Aikake Information Criterion technique for the selection of demographic and cytogenetic variables. The variables selected to build the model were International Staging System score, Eastern Cooperative Oncology Group score and the patient’s age. We found a significant negative impact on survival for TP53 mutations (progression-free survival: hazard ratio, 3.68; 95% confidence interval: 1.45–9.29, P=0.005; overall survival: hazard ratio, 9.07; 95% confidence interval: 2.78–9.57, P=0.0002).

The genes and pathways found to be most frequently mutated in this study are consistent with those in previous reports (KRAS 21% versus 21%, NRAS 18% versus 16%, BRAF 7% versus 8% and TP53 8% versus 8%). The exception was DIS3, for which the mutational incidence increased from 9% to 19% due to the deep coverage which enabled the detection of a higher number of subclonal mutations (5/20). In addition, the VRF of mutated RAS genes (<50% in all cases) supports the hypothesis that newly diagnosed MM patients who are not exposed to selective pressure by a therapy are more likely to harbor subclonal than clonal RAS mutations. The detection of minor subclones has allowed the identification of a subgroup of patients with poor outcome who would not have been identified by their cytogenetic profile or clinical manifestation, including those negative for del(17p) but positive for TP53 mutations. Considering the detection threshold in whole-genome and whole-exome sequencing studies, very useful genetic information might be being overlooked. Additionally, the recent discovery that Cereblon is essential for the anti-MM activity of immunomodulatory drugs is especially relevant here because patients enrolled in the GEM100MA565 trial were all treated with lenalidomide, suggesting that downstream genes such as IKZF1, IKZF3, Ikaros and MYC should be additionally studied when biomarkers of lenalidomide resistance need to be identified.

In conclusion, this is the first prospective study addressing the role of targeted sequencing in a highly homogeneous series of elderly, newly diagnosed MM patients treated within a clinical trial. Despite the limited number of samples included in the study, the next-generation sequencing strategy used here was capable of detecting mutations in purified plasma cells in most patients. The affordability of next-generation sequencing together with the small sample requirement offers an excellent opportunity to introduce personalized medicine protocols into clinical practice and also to intensify the search for new biomarkers and therapeutic targets to improve treatment selection and survival of MM patients.
LETTERS TO THE EDITOR

Salud i-PFIS (IFI 14/00008) and Fondo de Investigación Sanitaria PI15/01484 awarded to Joaquín Martínez López

Correspondence: jmarti01@med.ucm.es
doi:10.3324/haematol.2018.188839

Information on authorship, contributions, and financial & other disclosures was provided by the authors and is available with the online version of this article at www.haematologica.org.

References